Regeneron Pharmac…
USUSDRegeneron Pharmaceuticals Inc (US:REGN) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 2. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par Uzņēmumu
- Tīmekļvietne
- regeneron.com
- Nozare
- Health Care · Biotechnology: Pharmaceutical Preparations
- Galvenā Mītne
- Eastview, United States
- Izpilddirektors
- Leonard S. Schleifer
- Darbinieki
- 15 410
- Dibināts
- 1988
- Apgrozībā Esošās Akcijas
- 101.14 milj.
- Brīvā Apgrozība
- 95.85 milj.
- Tirgus Kapitalizācija
- 75.65 mljrd. USD
- Iekšējās Personas
- 2.09%
- Institucionālie Investori
- 93.55%
- Nozare (SIC)
- Pharmaceutical Preparations
- ISIN
- US75886F1075
- LEI
- 549300RCBFWIRX3HYQ56
- P/E
- 19.1
- Izmaksas Koeficients
- 8.7%
- FCF
- 3.76 mljrd. USD
- Izmaksas / FCF
- 10%
- Parāds
- 1.99 mljrd. USDneto nauda
- Dividenžu Stāžs
- 1 g.
- Peļņa, FCF un izmaksātās dividendes — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Dividendes
Regeneron Pharmaceuticals Inc (REGN) izmaksā dividendes reizi ceturksnī. Gadā (12 mēneši līdz jaunākajam paziņotajam maksājumam): 3.7 USD par akciju (maksājumi: 4). Tas ir aptuveni 0.49% no pašreizējās akciju cenas. Pamatojoties uz maksājumu vēsturi, nākamais ex-dividendes datums tiek gaidīts ap 17.11.2026.
| Ex-Datums | Izmaksa | Summa | % | Veids | Tikeris |
|---|---|---|---|---|---|
| 2026-08-18 | 2026-08-31 | 0.9400 USD | 0.1/0.5 % | ceturkšņa | US:REGN |
| 2026-05-20 | 2026-06-04 | 0.9400 USD | 0.1/0.6 % | ceturkšņa | US:REGN |
| 2026-02-20 | 2026-03-05 | 0.9400 USD | 0.1/0.5 % | ceturkšņa | US:REGN |
| 2025-11-20 | 2025-12-05 | 0.8800 USD | 0.1/0.5 % | ceturkšņa | US:REGN |
| 2025-08-18 | 2025-09-03 | 0.8800 USD | 0.2/≈0.6 % | ceturkšņa | US:REGN |
| 2025-05-20 | 2025-06-06 | 0.8800 USD | 0.1/≈0.6 % | ceturkšņa | US:REGN |
| 2025-02-20 | 2025-03-20 | 0.8800 USD | 0.1/0.1 % | vienreizējs | US:REGN |
Lielākie Akcionāri
| Turētājs | Daļa | Akcijas | Pārskata Datums |
|---|---|---|---|
| Blackrock Inc. | 9.01% | 9.11 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 6.56% | 6.63 milj. | 2026-06-30 |
| Dodge & Cox Inc. | 4.82% | 4.87 milj. | 2026-06-30 |
| State Street Corporation | 4.78% | 4.83 milj. | 2026-06-30 |
| Invesco Ltd. | 3.9% | 3.94 milj. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.73% | 3.77 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.23% | 3.27 milj. | 2026-06-30 |
| Vanguard Portfolio Manag… | 3.14% | 3.18 milj. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 3.09% | 3.12 milj. | 2026-06-30 |
| Franklin Resources, Inc. | 2.74% | 2.77 milj. | 2026-06-30 |
| Geode Capital Management… | 2.6% | 2.63 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.56% | 2.59 milj. | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.19% | 2.22 milj. | 2026-08-31 |
| Nuveen, LLC | 2% | 2.02 milj. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.32% | 1.33 milj. | 2026-08-31 |
| Fidelity Concord Street… | 1.28% | 1.29 milj. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.21% | 1.22 milj. | 2026-08-31 |
| PUTNAM LARGE CAP VALUE F… | 1.14% | 1.15 milj. | 2026-07-31 |
| YANCOPOULOS GEORGE D (Pr… | ≈1.11% | 1.13 milj. | 2025-12-31 |
| VANGUARD INDEX FUNDS-Van… | 1.1% | 1.12 milj. | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 1.06% | 1.07 milj. | 2026-07-31 |
| SCHLEIFER LEONARD S (Chi… | ≈0.68% | 687 981 | 2025-12-31 |
| MURPHY ANDREW J (Officer… | ≈0.06% | 56 437 | 2025-12-05 |
| LAROSA JOSEPH J (General… | ≈0.05% | 45 595 | 2026-08-19 |
| VAN PLEW DANIEL P (Offic… | ≈0.04% | 37 730 | 2025-12-05 |
| SING GEORGE LOUIS (Direc… | ≈0.03% | 33 157 | 2026-01-02 |
| FENIMORE CHRISTOPHER R (… | ≈0.02% | 23 505 | 2026-08-18 |
| RYAN ARTHUR F. (Director… | ≈0.02% | 17 303 | 2026-07-02 |
| MCCOURT MARION E (Office… | ≈0.02% | 15 567 | 2025-12-05 |
| BROWN MICHAEL S (Directo… | ≈0.01% | 12 865 | 2026-01-02 |
